ROR2 and non-small cell lung carcinoma: An interim analysis of a Phase 2 antibody drug conjugate targeting ROR2 in patients with NSCLC is expected in 2023 (https://biopharmaapac.com/news/31/2177/himalaya-therapeutics-announces-highlights-of-recent-clinical-progress.html, accessed on 21 December 2022).